G. Linette
Genetics · 2010–2019
A researcher in the Science corpus: 13 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Genetics — 19 citations into it
Whom G. Linette trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts G. Linette overall
Papers from G. Linette's perspective
Ordered by how strongly the researchers G. Linette trusts endorse each paper. Same corpus, a different order for every researcher.
- Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy (Journal of immunotherapy)
- Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. (Journal of Clinical Oncology)
- Integrative Genomics Viewer (Nature Biotechnology)
- The Sequence Alignment/Map format and SAMtools (Bioinform.)
- Prediction of MHC class I binding peptides using profile motifs. (Human Immunology)
- NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence
- The immune epitope database (IEDB) 3.0 (Nucleic Acids Res.)
- SomaticSniper: identification of somatic point mutations in whole genome sequencing data (Bioinform.)
- NetMHCpan, a method for MHC class I binding prediction beyond humans
- A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data (Bioinform.)
Their papers
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (2010) — 14,544 citations
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells (2015) — 1,091 citations
- pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens (2016) — 392 citations
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (2015) — 2,546 citations
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (2015) — 2,625 citations
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. (2013) — 1,129 citations
- Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. (2013) — 719 citations
- A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma (2019) — 613 citations
- Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma (2016) — 835 citations
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial (2016) — 1,083 citations
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. (2015) — 2,318 citations
- Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells (2013) — 660 citations
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. (2010) — 1,146 citations